>>> US Research Calls I

Research Calls I
  • Upgrades:
    • BNY Mellon (BK) upgraded to Outperform from Mkt Perform at Keefe Bruyette; tgt raised to $70
    • Petrobras (PBR) upgraded to Buy from Neutral at BofA Securities
    • Qiagen (QGEN) upgraded to Outperform from Peer Perform at Wolfe Research; tgt $50
  • Downgrades:
    • 10x Genomics (TXG) downgraded to Peer Perform from Outperform at Wolfe Research
    • Agilent (A) downgraded to Peer Perform from Outperform at Wolfe Research
    • Centuri Holdings (CTRI) downgraded to Underperform from Neutral at BofA Securities; tgt lowered to $21
    • Lyell Immunopharma (LYEL) downgraded to Neutral from Buy at H.C. Wainwright; tgt lowered to $1
    • Rio Tinto (RIO) downgraded to Hold from Buy at Berenberg
    • U.S. Bancorp (USB) downgraded to Neutral from Overweight at JP Morgan; tgt $43.50
  • Others:
    • ACADIA Pharmaceuticals (ACAD) initiated with an Outperform at BMO Capital Markets; tgt $31
    • Arcadium Lithium (ALTM) initiated with a Neutral at Goldman; tgt $4.30
    • BWX Technologies (BWXT) initiated with a Buy at Janney; tgt $113
    • CARGO Therapeutics (CRGX) initiated with an Overweight at Piper Sandler; tgt $37
    • Crescent Energy Company (CRGY) initiated with an Overweight at KeyBanc Capital Markets; tgt $16
    • Denison Mines (DNN) initiated with a Buy at ROTH MKM
    • Dianthus Therapeutics (DNTH) initiated with an Overweight at Cantor Fitzgerald
    • Dynatrace (DT) initiated with a Neutral at Piper Sandler; tgt $50
    • Exact Sciences (EXAS) initiated with a Sector Outperform at Scotiabank; tgt $70
    • Grab (GRAB) initiated with an Outperform at Mizuho; tgt $5
    • Hologic (HOLX) initiated with an Overweight at Stephens; tgt $87
    • Jasper Therapeutics (JSPR) initiated with a Buy at Stifel; tgt $86
    • Kyndryl (KD) initiated with an Outperform at Oppenheimer; tgt $33
    • Myriad Genetics (MYGN) initiated with a Sector Outperform at Scotiabank; tgt $29
    • Nautilus Biotechnology (NAUT) initiated with a Buy at Guggenheim; tgt $6
    • Neurogene (NGNE) initiated with an Outperform at BMO Capital Markets; tgt $65
    • PagerDuty (PD) initiated with a Neutral at JP Morgan; tgt $24
    • SOPHiA GENETICS SA (SOPH) initiated with a Buy at Guggenheim; tgt $6
    • Taysha Gene Therapies (TSHA) initiated with an Outperform at BMO Capital Markets; tgt $5
    • Vertex Pharma (VRTX) initiated with a Buy at Redburn Atlantic; tgt $545
    • Viking Therapeutics (VKTX) initiated with an Overweight at Morgan Stanley; tgt $105